Indofarma Tbk. vs Solusi Bangun Indonesia Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Solusi Bangun Indonesia Tbk. trades at Rp775 (market cap 6.99T). The key difference: Solusi Bangun Indonesia Tbk. is far larger — about 17.9× Indofarma Tbk.'s market cap. Which is the better fit depends on your goals.
| INAF | SMCB | |
|---|---|---|
Market Cap | 390.51B | 6.99T |
Trailing returns across standard periods
Latest headlines on both assets
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Read more on INAF →PT Holcim Indonesia Tbk (the Company) was originally a joint venture between a subsidiary of Kaiser Cement and Gypsum Corp. and PT Semen Gresik. Founded in 1971, the company owns a factory in Narogong, West Java, with an annual capacity of 3 million tons. The Company changed its foreign capital investment status (PMA) to domestic capital investment (PMDN) based on the approval from Chairman of Capital Investment Coordinating Board No. 17/V/1988 dated November 19, 1988. Effective January 1, 2006, the Company changed its name from PT Semen Cibinong Tbk. to PT Holcim Indonesia Tbk.
Read more on SMCB →